StreetInsider.com News Articles

StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 8-K bioAffinity Technologies For: Jul 27 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+27/26816635.html si-local-file:///var/storage/secattach/20260727/26816635.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+27/26816635.html Mon, 27 Jul 2026 08:30:00 -0400 BIAF O.22213627 Form 8-K bioAffinity Technologies For: Jul 27 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+27/26816635.html si-local-file:///var/storage/secattach/20260727/26816635.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+27/26816635.html Mon, 27 Jul 2026 08:30:00 -0400 BIAF O.22213627 bioAffinity publishes clinical framework for CyPath Lung nodule testing http://www.streetinsider.com/Corporate+News/bioAffinity+publishes+clinical+framework+for+CyPath+Lung+nodule+testing/26816472.html <p>bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) has published a clinical review and white paper outlining specialty-specific protocols for using its CyPath® Lung test in pulmonary nodule evaluation and cancer surveillance.</p><p>The paper, authored by Chief Medical Officer Gordon H. Downie, MD, PhD, is titled "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer." It proposes clinical pathways for three care settings: primary care practices managing incidentally discovered pulmonary nodules, pulmonary nodule and interventional pulmonology programs evaluating patients for biopsy, and oncology practices conducting surveillance of cancer survivors.</p><p>The publication draws on http://www.streetinsider.com/Corporate+News/bioAffinity+publishes+clinical+framework+for+CyPath+Lung+nodule+testing/26816472.html Mon, 27 Jul 2026 08:09:12 -0400 BIAF BIAFW bioAffinity publishes clinical framework for CyPath Lung nodule testing http://www.streetinsider.com/Corporate+News/bioAffinity+publishes+clinical+framework+for+CyPath+Lung+nodule+testing/26816472.html <p>bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) has published a clinical review and white paper outlining specialty-specific protocols for using its CyPath® Lung test in pulmonary nodule evaluation and cancer surveillance.</p><p>The paper, authored by Chief Medical Officer Gordon H. Downie, MD, PhD, is titled "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer." It proposes clinical pathways for three care settings: primary care practices managing incidentally discovered pulmonary nodules, pulmonary nodule and interventional pulmonology programs evaluating patients for biopsy, and oncology practices conducting surveillance of cancer survivors.</p><p>The publication draws on http://www.streetinsider.com/Corporate+News/bioAffinity+publishes+clinical+framework+for+CyPath+Lung+nodule+testing/26816472.html Mon, 27 Jul 2026 08:09:12 -0400 BIAF BIAFW bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html <p class="bwalignc"> <b><i>Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway</i></b> </p><p class="bwalignc"> <b><i>Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.bioaffinitytech.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=b5d57a36185b892a5a41ef4184d9bafa" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>,<b> </b>a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cypathlung.com%2Fwp-content%2Fuploads%2F2026%2F07%2FCyPath-Lung_Pulmonary-Nodules-et-al_White-Paper_G-Downie_July-2026.pdf&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=clinical+review+and+white+paper&index=2&md5=88779e40e21a23032dd9dc95d931e459" shape="rect">clinical review and white paper</a> authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54577457&newsitemid=20260727737775&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=3&md5=5f3f7ff969a4d9ba868ce25fde48a2da" http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+Publishes+New+Clinical+Framework+Addressing+Growing+Market+for+Pulmonary+Nodule+Risk+Stratification+and+Early+Lung+Cancer+Detection+Using+CyPath%C2%AE+Lung/26816464.html Mon, 27 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 Form 8-K bioAffinity Technologies For: Jul 22 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+22/26798803.html si-local-file:///var/storage/secattach/20260722/26798803.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+22/26798803.html Wed, 22 Jul 2026 08:30:00 -0400 BIAF O.22213627 Form 8-K bioAffinity Technologies For: Jul 22 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+22/26798803.html si-local-file:///var/storage/secattach/20260722/26798803.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+22/26798803.html Wed, 22 Jul 2026 08:30:00 -0400 BIAF O.22213627 bioAffinity Technologies partners with Pictor to develop asthma and COPD tests http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+partners+with+Pictor+to+develop+asthma+and+COPD+tests/26798644.html <p>bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) announced a collaboration with Pictor, Inc. to develop and commercialize diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD), according to a press release from the company.</p><p>The agreement combines bioAffinity's flow cytometry platform with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles associated with airway inflammation. The tests are intended to help physicians identify the inflammatory pathways driving an individual patient's disease and support treatment decisions, including the use of FDA-approved biologics.</p><p>bioAffinity holds multiple patents pending related to its asthma and COPD testing platform and will retain intellectual http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+partners+with+Pictor+to+develop+asthma+and+COPD+tests/26798644.html Wed, 22 Jul 2026 08:11:04 -0400 BIAF BIAFW bioAffinity Technologies partners with Pictor to develop asthma and COPD tests http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+partners+with+Pictor+to+develop+asthma+and+COPD+tests/26798644.html <p>bioAffinity Technologies, Inc. (Nasdaq: BIAF, BIAFW) announced a collaboration with Pictor, Inc. to develop and commercialize diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD), according to a press release from the company.</p><p>The agreement combines bioAffinity's flow cytometry platform with Pictor's targeted proteomic analysis platform to analyze immune cell populations and cytokine profiles associated with airway inflammation. The tests are intended to help physicians identify the inflammatory pathways driving an individual patient's disease and support treatment decisions, including the use of FDA-approved biologics.</p><p>bioAffinity holds multiple patents pending related to its asthma and COPD testing platform and will retain intellectual http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+partners+with+Pictor+to+develop+asthma+and+COPD+tests/26798644.html Wed, 22 Jul 2026 08:11:04 -0400 BIAF BIAFW bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html <p class="bwalignc"> <b><i>Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide</i></b> </p><p class="bwalignc"> <b><i>Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics</i></b> </p><p class="bwalignc"> <b><i>Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile</i></b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54574783&newsitemid=20260722558457&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=f0b616739e4fc0b31d9c950a3f2b7d1d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW),</b> a biotechnology company advancing early-stage cancer diagnostics and http://www.streetinsider.com/Business+Wire/bioAffinity+Technologies+and+Pictor%C2%AE%2C+Inc.+Partner+to+Develop+and+Commercialize+bioAffinity%E2%80%99s+Diagnostics+for+Asthma+and+COPD/26798626.html Wed, 22 Jul 2026 08:08:00 -0400 BIAF BIAFW O.22213627 Form 8-K bioAffinity Technologies For: Jul 07 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+07/26739367.html si-local-file:///var/storage/secattach/20260707/26739367.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+07/26739367.html Tue, 07 Jul 2026 08:54:00 -0400 BIAF O.22213627 Form 8-K bioAffinity Technologies For: Jul 07 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+07/26739367.html si-local-file:///var/storage/secattach/20260707/26739367.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++bioAffinity+Technologies++For%3A+Jul+07/26739367.html Tue, 07 Jul 2026 08:54:00 -0400 BIAF O.22213627 bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+Q2+CyPath+Lung+sales+rise+over+200%25+year-over-year/26739321.html <p>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reported that sales volume of its CyPath® Lung diagnostic test grew more than 200% year-over-year in the second quarter of 2026, according to a company press release.</p><p>The number of tests sold in Q2 2026 also increased more than 30% compared with the first quarter of 2026. The company attributed the growth to higher utilization among existing clients and a 155% increase in the number of physician offices ordering the test compared with Q2 2025.</p><p>The company said it has performed nearly 3,000 CyPath® Lung tests since the product's commercial launch. The test is used across http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+Q2+CyPath+Lung+sales+rise+over+200%25+year-over-year/26739321.html Tue, 07 Jul 2026 08:46:44 -0400 BIAF BIAFW bioAffinity Technologies Q2 CyPath Lung sales rise over 200% year-over-year http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+Q2+CyPath+Lung+sales+rise+over+200%25+year-over-year/26739321.html <p>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) reported that sales volume of its CyPath® Lung diagnostic test grew more than 200% year-over-year in the second quarter of 2026, according to a company press release.</p><p>The number of tests sold in Q2 2026 also increased more than 30% compared with the first quarter of 2026. The company attributed the growth to higher utilization among existing clients and a 155% increase in the number of physician offices ordering the test compared with Q2 2025.</p><p>The company said it has performed nearly 3,000 CyPath® Lung tests since the product's commercial launch. The test is used across http://www.streetinsider.com/Corporate+News/bioAffinity+Technologies+Q2+CyPath+Lung+sales+rise+over+200%25+year-over-year/26739321.html Tue, 07 Jul 2026 08:46:44 -0400 BIAF BIAFW bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies%E2%80%99+Quarterly+CyPath%C2%AE+Lung+Sales+Double+to+New+Record+as+Commercial+Momentum+Continues/26739316.html <p class="bwalignc"> <b>CyPath® Lung sales volume for Q2 2026 grows more than 200% year-over-year and 30% over record-breaking prior quarter</b> </p><p class="bwalignc"> <b>Growth in Q2 driven by increasing utilization among existing clients and 155% increase in physician offices ordering CyPath® Lung as compared to Q2 2025</b> </p> <p> SAN ANTONIO--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbioaffinitytech.com%2F&esheet=54566082&newsitemid=20260707410622&lan=en-US&anchor=bioAffinity+Technologies%2C+Inc.&index=1&md5=6a7d243ae3f477a55a7c886b85eb902d" shape="rect"><b>bioAffinity Technologies, Inc.</b></a><b> (Nasdaq: BIAF; BIAFW)</b>, a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cypathlung.com&esheet=54566082&newsitemid=20260707410622&lan=en-US&anchor=CyPath%26%23174%3B+Lung&index=2&md5=40de7d553e1e5d3b661b1d2e082ff8fb" shape="rect">CyPath® Lung</a>, its noninvasive lung cancer diagnostic, with http://www.streetinsider.com/Press+Releases/bioAffinity+Technologies%E2%80%99+Quarterly+CyPath%C2%AE+Lung+Sales+Double+to+New+Record+as+Commercial+Momentum+Continues/26739316.html Tue, 07 Jul 2026 08:46:00 -0400 BIAF BIAFW O.22213627